We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.6B
AUM Growth
+$151M
Cap. Flow
-$15.9M
Cap. Flow %
-0.61%
Top 10 Hldgs %
41.87%
Holding
167
New
13
Increased
21
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$23.6M
3
VTRS icon
Viatris
VTRS
+$18.4M
4
ABT icon
Abbott
ABT
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.7M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$20.5M
2
HCA icon
HCA Healthcare
HCA
+$18.3M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.9M
4
MDVN
MEDIVATION, INC.
MDVN
+$15.5M
5
STJ
St Jude Medical
STJ
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Real Estate 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
51
Cardinal Health
CAH
$53.2B
$11.8M 0.46%
+152,500
New +$12.3M
SNY icon
52
Sanofi
SNY
$103B
$11.6M 0.45%
305,000
– –
SBRA icon
53
Sabra Healthcare REIT
SBRA
$5.38B
$11.5M 0.44%
456,190
– –
DOC
54
DELISTED
PHYSICIANS REALTY TRUST
DOC
$11.4M 0.44%
530,672
– –
BDX icon
55
Becton Dickinson
BDX
$45.6B
$11.3M 0.44%
+64,655
New +$11.1M
CI icon
56
Cigna
CI
$76.1B
$11.3M 0.43%
+86,400
New +$11.3M
UTHR icon
57
United Therapeutics
UTHR
$26.2B
$11M 0.42%
93,100
– –
VTR icon
58
Ventas
VTR
$44.7B
$10.8M 0.41%
152,491
– –
DVA icon
59
DaVita
DVA
$15.3B
$10.6M 0.41%
+161,100
New +$11.3M
PRTK
60
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$9.92M 0.38%
762,581
– –
ELGX
61
DELISTED
Endologix Inc
ELGX
$9.9M 0.38%
77,350
+22,250
+40% +$2.85M
NTRA icon
62
Natera
NTRA
$38.6B
$9.8M 0.38%
882,358
– –
CRL icon
63
Charles River Laboratories
CRL
$11.3B
$9.58M 0.37%
+115,000
New +$9.64M
LKFT
64
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$9.55M 0.37%
147,738
– –
ARDX icon
65
Ardelyx
ARDX
$1.25B
$9.16M 0.35%
707,636
-681,734
-49% -$7.14M
FOMX
66
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$8.95M 0.34%
966,065
– –
AVDL
67
DELISTED
Avadel Pharmaceuticals
AVDL
$7.74M 0.3%
624,288
– –
PVLA
68
Palvella Therapeutics
PVLA
$2.15B
$7.59M 0.29%
51,824
+3,722
+8% +$495K
CLLS
69
Cellectis
CLLS
$287M
$7.47M 0.29%
310,250
– –
TVTX icon
70
Travere Therapeutics
TVTX
$5.33B
$7.38M 0.28%
329,949
– –
HCA icon
71
HCA Healthcare
HCA
$85.7B
$7.24M 0.28%
95,684
-239,314
-71% -$18.3M
EXEL icon
72
Exelixis
EXEL
$14.1B
$7.06M 0.27%
551,647
-853,773
-61% -$9.23M
ARIA
73
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$6.87M 0.26%
502,000
– –
SAGE
74
DELISTED
Sage Therapeutics
SAGE
$6.76M 0.26%
146,800
– –
RARE icon
75
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.27M 0.24%
88,400
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Tekla Capital Management held 167 positions worth $2.6B, up 6.1% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2016 filing shows 13 new, 21 increased, 24 reduced and 25 closed positions. Its largest new stake was Cardinal Health: 152,500 shares worth $11.8M. The largest sale was Illumina, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2016 buy was Cardinal Health: 152,500 shares worth $11.8M.
  • Tekla Capital Management added most to Merck in Q3 2016, an estimated $27.5M increase.
  • Tekla Capital Management's biggest Q3 2016 reduction was Illumina, cutting an estimated $20.5M.
  • Tekla Capital Management fully exited State Street SPDR S&P Biotech ETF in Q3 2016, selling an estimated $15.9M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.6B portfolio in Q3 2016.
  • Tekla Capital Management opened 13 new positions and closed 25 in Q3 2016.
  • Tekla Capital Management's portfolio value rose 6.1% quarter-over-quarter to $2.6B.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.